Weggen Jan Tobias, Bean Ryan, Hui Kimberly, Wendeler Michaela, Hubbuch Jürgen
Institute of Process Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany.
Purification Process Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, MD, United States.
Front Bioeng Biotechnol. 2024 Jul 11;12:1403644. doi: 10.3389/fbioe.2024.1403644. eCollection 2024.
The conjugation reaction is the central step in the manufacturing process of antibody-drug conjugates (ADCs). This reaction generates a heterogeneous and complex mixture of differently conjugated sub-species depending on the chosen conjugation chemistry. The parametrization of the conjugation reaction through mechanistic kinetic models offers a chance to enhance valuable reaction knowledge and ensure process robustness. This study introduces a versatile modeling framework for the conjugation reaction of cysteine-conjugated ADC modalities-site-specific and interchain disulfide conjugation. Various conjugation kinetics involving different maleimide-functionalized payloads were performed, while controlled gradual payload feeding was employed to decelerate the conjugation, facilitating a more detailed investigation of the reaction mechanism. The kinetic data were analyzed with a reducing reversed phase (RP) chromatography method, that can readily be implemented for the accurate characterization of ADCs with diverse drug-to-antibody ratios, providing the conjugation trajectories of the single chains of the monoclonal antibody (mAb). Possible kinetic models for the conjugation mechanism were then developed and selected based on multiple criteria. When calibrating the established model to kinetics involving different payloads, conjugation rates were determined to be payload-specific. Further conclusions regarding the kinetic comparability across the two modalities could also be derived. One calibrated model was used for an exemplary screening of the initial concentrations offering valuable insights for profound understanding of the conjugation process in ADC development.
偶联反应是抗体药物偶联物(ADC)制造过程中的核心步骤。根据所选的偶联化学方法,该反应会产生由不同偶联亚类组成的异质且复杂的混合物。通过机理动力学模型对偶联反应进行参数化,为增强有价值的反应知识和确保过程稳健性提供了机会。本研究介绍了一种用于半胱氨酸偶联的ADC模式(位点特异性和链间二硫键偶联)偶联反应的通用建模框架。进行了涉及不同马来酰亚胺功能化有效载荷的各种偶联动力学研究,同时采用受控的逐步有效载荷进料来减缓偶联反应,便于更详细地研究反应机理。采用还原反相(RP)色谱法分析动力学数据,该方法可轻松用于准确表征具有不同药物与抗体比率的ADC,提供单克隆抗体(mAb)单链的偶联轨迹。然后根据多个标准开发并选择了可能的偶联机理动力学模型。在校准已建立的模型以适应涉及不同有效载荷的动力学时,确定偶联速率是有效载荷特异性的。还可以得出关于两种模式之间动力学可比性的进一步结论。一个校准模型用于对初始浓度进行示例性筛选,为深入理解ADC开发中的偶联过程提供了有价值的见解。